🇺🇸 FDA

Intelligence · Patent portfolio

SANGAMO THERAPEUTICS Patents

Full USPTO pharma patent portfolio for SANGAMO THERAPEUTICS — grant dates, expiration, and drug cross-links.

Patents
192
Expiring ≤24m
7

Quick answer

SANGAMO THERAPEUTICS has 192 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 7 expire within 24 months — use filters for patent-cliff planning.

Page 1 of 4

  1. US 12318427

    Methods and compositions for modulation of tau proteins

    Expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12139517

    Modulators of chromosome 9 open reading frame 72 gene expression and uses thereof

    Expires Mon Nov 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12043650

    Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (CFTR) gene

    Expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11981967

    Engineering AAV

    Expires Mon May 09 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11981739

    Chimeric antigen receptor specific for interleukin-23 receptor

    Expires Mon May 09 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11920169

    Compositions for linking DNA-binding domains and cleavage domains

    Expires Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11898158

    Methods and compositions for the treatment of lysosomal storage diseases

    Expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11884930

    Method of inactivating a glucocorticoid receptor gene in an isolated cell

    Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11857641

    Method for the treatment of mucopolysaccharidosis type I

    Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11859190

    Methods and compositions for regulation of transgene expression

    Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11845965

    Regulation of gene expression using engineered nucleases

    Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11827900

    Engineered target specific nucleases

    Expires Mon Nov 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11814432

    Anti-HLA-A2 antibodies, related chimeric antigen receptors, and uses thereof

    Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11793888

    Methods and compositions for engineering immunity

    Expires Mon Oct 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11723952

    Methods and compositions for treating Huntington's Disease

    Expires Mon Aug 10 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11718834

    Compositions and methods for producing recombinant AAV

    Expires Mon Aug 03 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11690921

    Delivery of target specific nucleases

    Expires Mon Jun 29 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11661611

    Genetic modification of cytokine inducible SH2-containing protein (CISH) gene

    Expires Mon May 25 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11661612

    DNA-binding proteins and uses thereof

    Expires Mon May 25 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11655275

    Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (CFTR) gene

    Expires Mon May 18 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11649468

    Targeted integration into the PPP1R12C locus

    Expires Mon May 11 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11648267

    Methods and compositions for gene inactivation

    Expires Mon May 11 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 11639504

    Methods and compositions for regulation of transgene expression

    Expires Mon Apr 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 11634463

    Methods and compositions for treating hemophilia

    Expires Mon Apr 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 11608492

    Compositions for linking DNA-binding domains and cleavage domains

    Expires Mon Mar 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 11591622

    Method of making and using mammalian liver cells for treating hemophilia or lysosomal storage disorder

    Expires Mon Feb 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 11512287

    Targeted disruption of T cell and/or HLA receptors

    Expires Mon Nov 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 11504389

    Tau modulators and methods and compositions for delivery thereof

    Expires Mon Nov 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 11492643

    Methods and compositions for treatment of a genetic condition

    Expires Mon Nov 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 11452782

    Liver-specific constructs factor VIII expression cassettes and methods of use thereof

    Expires Mon Sep 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 11439666

    Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases

    Expires Mon Sep 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 11421007

    Zinc finger protein compositions for modulation of huntingtin (Htt)

    Expires Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 11401512

    Engineered target specific nucleases

    Expires Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 11352631

    Targeted disruption of the T cell receptor

    Expires Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 11311574

    Methods and compositions for targeted cleavage and recombination

    Expires Mon Apr 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 11285175

    Targeted disruption of the MHC cell receptor

    Expires Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 11235026

    Methods and compositions for modulating PD1

    Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 11236175

    T cell modifying compounds and uses thereof

    Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 11219695

    Methods and compositions for the treatment of Fabry disease

    Expires Mon Jan 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 11149321

    Methods and compositions for targeted single-stranded cleavage and targeted integration

    Expires Mon Oct 14 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 11123443

    Htt repressors and uses thereof

    Expires Mon Sep 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 11110154

    Methods and compositions for treating Huntington's Disease

    Expires Mon Sep 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 11040115

    Method for the treatment of lysosomal storage diseases

    Expires Mon Jun 17 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 11041174

    Compositions for linking DNA-binding domains and cleavage domains

    Expires Mon Jun 17 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 11021696

    Nuclease-mediated regulation of gene expression

    Expires Mon May 27 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 11020492

    Gene correction of SCID-related genes in hematopoietic stem and progenitor cells

    Expires Mon May 27 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10975375

    Methods and compositions for regulation of transgene expression

    Expires Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10975393

    Engineered target specific nucleases

    Expires Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does SANGAMO THERAPEUTICS have?

192 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do SANGAMO THERAPEUTICS patents expire?

7 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.